Debbie Dumont, co-founder of Bioqube Ventures, and one of In Vivo’s Rising Leaders, talks about the company’s investment model, Europe’s translational challenges, and aligning passion and purpose to find ultimate fulfilment.
Debbie Dumont is part of a new generation of investors, seeking to create value among ideas that may not have a clear pathway ahead. She does this through her co-founded investment firm, Bioqube Ventures, which she started in 2015 with her husband Nico Vandervelpen.
Via a “slight detour” whereby it co-managed an investment and incubation model for a large pharmaceutical company in Belgium, in...
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approvals in Europe and the US. She talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.
Neha Krishnamohan, CFO of Artiva Biotherapeutics, brings Wall Street precision to biotech innovation, helping lead the company through a successful IPO while advancing NK cell therapies for cancer and autoimmune diseases.
